Skip to main content
SpringerLink
Log in

Epitheliale Ovarialkarzinome

  • Chapter
Kompendium Internistische Onkologie

  • 12 Accesses

Zusammenfassung

Häufigkeit/Inzidenz:Die Neuerkrankungsrate ist stark altersabhängig. Sie steigt von ca. 15 Neuerkrankungen pro 100 000 Frauen/Jahr in der Altersgruppe der 40- bis 44jährigen auf 54 pro 100 000 Frauen/Jahr in der Altersgruppe der 75- bis 79jährigen an (Yancik et al. 1986). Das mittlere Alter bei der Diagnosestellung beträgt 58 Jahre.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Advanced Ovarian Cancer Trials Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical tirals. BMJ 303: 884–893

    Article  Google Scholar 

  • Alberts DS, Green S, Hannigan EV, O’Toole R et al. (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–717

    PubMed  CAS  Google Scholar 

  • Alberts DS, Liu PY, Hannigan EV, O’Toole T et al. (1995) Phase III study of i.p. cisplatin/cyclophosphamid versus i.v. cisplatin/i.v. cyclophosphamide in the treatment of nonmeasurable optimal stage III ovarian cancer. Proc IGCS Philadelphia 1995 (abstract)

    Google Scholar 

  • Anderson H, Wagstaff J, Crowther D et al. (1988) Cooperative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin

    Google Scholar 

  • Averette HE, Hoskins W, Nguyen HN et al. (1993) National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer 71: 1629–1638

    PubMed  CAS  Google Scholar 

  • Bauknecht TH, Birmelin G, Kommoss F (1990) Clinical significance of oncogenes and growth factors in ovarian cancer. Steroid Biochem Mol Biol 37: 855–862

    Article  CAS  Google Scholar 

  • Berchuk A, Rodrigues GC, Kamel A, Doge RK et al. (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian carcinoma in correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164: 669–674

    Article  Google Scholar 

  • Berek JS, Hacker NF (1987) Staging and secon look operations in ovarian cancer. In: Piver MS (ed) Ovarian malignancies. Edinburgh, Churchill Livingstone, p 112

    Google Scholar 

  • Berek JS, Hacker NF, Lichtenstein A et al. (1985) Intraperitonel recombinant alpha interferon for salvage immunotherapy in stage III epithelial ovarian cancer: A GOG study. Cancer Res 45: 44–47

    Google Scholar 

  • Berej JP, Langley FA, Talerman A, Delemarre JF (1989) The prognostic variability of ovarian tumor grading by different pathologists. Gynecol Oncol 27: 166

    Google Scholar 

  • Bolis G, Colombo N, Favalli G et al. (1992) Randomized multicenter clinical trial in stage I epithelial ovarian cancer. Proc ASCO 11: 225

    Google Scholar 

  • Bookman M, Godfrey S, Padavic K et al. (1990) Anti-transferrin receptor immunotoxin therapy: Phase I intraperitoneal trial. Proc ASCO 9: 772

    Google Scholar 

  • Bourne TH, Whitehead MI, Campell S et al. (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43: 92–97

    Article  PubMed  CAS  Google Scholar 

  • Bruzzone M, Repetto L, Chiara S, Campora E et al. (1990) Chemotherapy versus radiotherapy in the management of ovarian cancer patient with pathological complete response or minimal residual disease at second look. Gynecol Oncol 37: 367–373

    Article  Google Scholar 

  • Burgh MEL van der, Lent M van, Kobierska A et al. (1993) Intervention debulking surgery does improve survival in advanced epithelial ovarian cancer: an EORTC Gynecological Cancer Cooperative group study. Proc. ASCO 12: 258

    Google Scholar 

  • Burgh MEL van der, Lent M van, Buyse M, Kobierska A et al. (1995) The effect debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–634

    Article  Google Scholar 

  • Burghardt E, Winter R (1989) The effect of chemotherapy on lymph node metastases in ovarian cancer. Baillieres Clin Obstet Gynecol 3: 167–171

    Article  CAS  Google Scholar 

  • Calvert AH, Newell DR, Gumbrell LA et al. (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function 7: 1748–1756

    CAS  Google Scholar 

  • Chiara S, Conte PF, Bruzzone M et al. (1987) Cisplatin and cyclophosphamide in early epithelial ovarian cancer. Chemotherapia 6: 380–383

    CAS  Google Scholar 

  • Colombo N, Pettili M, Parma G et al. (1993) Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose versus dose intense cisplatin chemotherapy. Proc ASCO 12: 255

    Google Scholar 

  • Cramer DW, Welch WR, Scully RE, Wojciechowski CA (1982) Ovarian cancer and talc. Cancer 50: 372–376

    Article  PubMed  CAS  Google Scholar 

  • Cramer DW, Willett WC, Bell DA et al. (1989) Galactose consumption and metabolism in relation to risk of ovarian cancer. Lancet 2: 66

    Article  PubMed  CAS  Google Scholar 

  • Declos L, Smiths JP (1975) Ovarian cancer with special regard to types of radiotherapy. NCI Monogr 42: 129

    Google Scholar 

  • Dembo AJ, Bush RS, Beale FA et al. (1979) The Princess Margaret Hospital study of ovarian cancer: stages I, II and asymptomatic III presentations. Cancer Treat Rep 63: 249

    CAS  Google Scholar 

  • Dembo AJ, Bush RS, Beale FA et al. (1979a) Improved survival following abdomino-pelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol 134: 793–800

    Google Scholar 

  • DiCioccio A, Piver ST (1992) The genetics of ovarian cancer. Cancer Invest 10: 135–141

    Article  PubMed  CAS  Google Scholar 

  • Dottino PR, Plaxe SC, Cohen CJ (1991) A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 43: 203–205

    Article  PubMed  CAS  Google Scholar 

  • Eifel PJ, Gershenson DM, Declos L, Stringer C et al. (1991) Twice dayly split course abdominopelvic radiation therapy after chemotherapy and positive second look laparotomy for epithelial ovarian carcinoma. Int J Radiat Oncol Biol Phys 21: 1013–1018

    Article  PubMed  CAS  Google Scholar 

  • Einhorn N, Sjovall K, Knapp R, Hall P et al. (1992) Specificity of serum Ca 125 radioimmunoassay for early detection of ovarian cancer: a prospective study. Obstet Gynecol 80: 14

    PubMed  CAS  Google Scholar 

  • Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. (1994) Europeancanadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12: 2654–2666

    Google Scholar 

  • Epenetos AA, Hooker G, Krausz T et al. (1987) Antibody-guided irradiation of advanced ovarian cancer with intraaperitoneally administered radiolabelled monoclonal antibodies J Clin Oncol 5: 118–90

    Google Scholar 

  • FIGO Cancer Comittee (1990) Staging announcement Gynecol Oncol 25: 40

    Google Scholar 

  • Funks Z (1977) The role of radiation therapy in the management of ovarian carcinoma. Isr J Med Sci 13: 815

    Google Scholar 

  • Gallion HH, Powell DE, Morrow JK et al. (1992) Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 47: 137–142

    Article  PubMed  CAS  Google Scholar 

  • Greene MH, Clark JW, Blayney DW (1984) The epidemiology of ovarian cancer. Semin Oncol 11: 209–226

    PubMed  CAS  Google Scholar 

  • Griffiths CT, Parker LM, Fuller AM (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235

    PubMed  CAS  Google Scholar 

  • Hacker NF, Berek JS, Lagasse LD (1983) Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61: 413

    PubMed  CAS  Google Scholar 

  • Hatch KD, Beecham JB, Blessing JA, Creasman WT et al. (1991) Responsivness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 68: 269–271

    Article  PubMed  CAS  Google Scholar 

  • Heintz AM, Hacker NF, Berek JS (1986) Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67: 783

    Article  PubMed  CAS  Google Scholar 

  • Henriksen R, Strang P, Wilander E et al. (1994) p53 Expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, ki-67 expression and flow cytometry. Gynecol Oncol 53: 301–306

    Article  PubMed  CAS  Google Scholar 

  • Hoskins WJ, Rubin SC, Dulaney E et al. (1989) Influence of secondary cytoreduction at the time of second look laparotomy on the survival of patients with epithelial ovarian cancer. Gynecol Oncol 34: 365

    Article  PubMed  CAS  Google Scholar 

  • Hreshchyshyn MW, Park RC, Blesing JA et al. (1980) The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 138: 139

    PubMed  CAS  Google Scholar 

  • Hunter RW, Alexander NDE, Soutter WP, Welch WR (1992) Metaanalysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinat of prognosis? Am J Obstet Gynecol 166 (2): 504–511

    Article  PubMed  CAS  Google Scholar 

  • Kacinski B (1993) Ovarian carcinoma: Tumor-and molecular biology. In: Meerpohl HG, Pfleiderer A, Profus C (Hrsg) Das Ovarialkarzinom Bd 1: Tumorbiologie, Screening, Staging. Springer, Berlin Heidelberg New York Tokyo, S 7–19

    Chapter  Google Scholar 

  • Kaye SB (1992) Importance of cisplatin dosage in advance ovarian cancer: survival benefit in a randomized trial. Proc ASCO 11: 226

    Google Scholar 

  • Kaern J, Trope C, Kjorstad KE, Abeler Vet al. (1990) Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 38: 452–457

    Article  PubMed  CAS  Google Scholar 

  • Kerlikowske K, Brown JS, Grady DG (1992) Should women with familial ovarian cancer undergo prophylactic oophorectony? Obstet Gynecol 80: 700–707

    PubMed  CAS  Google Scholar 

  • Kiechle-Schwarz M, Walz L, Pfleiderer A (1992) Der Verlust von genetischem Material vom kurzen Arm des Chromosoms 11: Ein häufiger Befund beim Ovarialkarzinom. In: Meerpohl HG, Pfleiderer A (Hrsg) Das Ovarialkarzinom Bd 1: Tumorbiologie, Screening, Staging. Springer, Berlin Heidelberg New York Tokyo, S 20–27

    Google Scholar 

  • Kindermann G (1995) Laparoscopic management of ovarian malignancies: data of an early follow up study in 273 german departments of GYN/OBST Proc. 47. Annual Meeting Soc Pelvic Surgeons, Lexington

    Google Scholar 

  • Klaassen D, Shelly W, Stainveld A et al. (1988) Early ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trial Group report. J Clin Oncol 6: 1254–1263

    PubMed  CAS  Google Scholar 

  • Lambert HE, Berry RJ (1985) High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer ( FIGO stages III and IV ): Report from the North Thames Cooperative Group. BMJ 290: 889–892

    Article  PubMed  CAS  Google Scholar 

  • Lambert JE, The North Thames Ovary Group (1989) Advanced carcinoma of the ovary: a comparative trial between carboplatin versus radiotherapy as maintenance therapy. Proc 2 International Gynecol Cancer Society, Toronto

    Google Scholar 

  • Lawton F, Luesly D, Blackledge G, Hilton C, Kelly K et al. (1990) A randomized trial comparing whole abdominal radiotherapy with chemotherapy follswing cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. Clin Oncol 2: 4

    Article  CAS  Google Scholar 

  • Levin L, Hryniuk WM (1987) Dose intensity analysis of chemnotherapy regimes in ovarian carcinoma. J Clin Oncol 5: 756–767

    PubMed  CAS  Google Scholar 

  • Levin L, Simon R, Hryniuk W (1993) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85 (21): 1732–1742

    Article  PubMed  CAS  Google Scholar 

  • Malkasian GD Jr, Melton LJ III, O’brien PC, Greene MH (1984) Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 149: 274–284

    PubMed  Google Scholar 

  • Mangioni C, Epis A, Vassena L, Scalambrino S et al. (1987) Radiotherapy (RT) versus chemotherapy (CH) as second treatment of minimal disease (MRD) in advanced epithelial ovarian cancer (EOC). Proc 1 International Gynecol Cancer Society, Amsterdam

    Google Scholar 

  • Markman M (1994) The role of intraperitoneal chemotherapy in ovarian cancer. Cancer Treat Res 70: 73–82

    Article  PubMed  CAS  Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF et al. (1992) A phase III trials of dose intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc ASCO 11: 226

    Google Scholar 

  • McGuire WP, Hoskins W, Brady M et al. (1993) A phase III trial comparing cisplatin/cytoxan and cisplatin/toxol in advanced ovarian cancer. Proc Am Soc Clin Oncol 12: 255

    Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334: 1–6

    CAS  Google Scholar 

  • Meerpohl HG (1984) Chemotherapie fortgeschrittener epithelialer Ovarialkarzinome. Onkologie 7 [Suppl 2]: 22–34

    Article  PubMed  Google Scholar 

  • Meerpohl HG, Giese E, Teufel G et al. (1987) Die sekundäre Tumorreduktion bei Patientinnen mit fortgeschrittenem Ovarialkarzinom. Arch Gynecol Obstet 242: 411–413

    Article  Google Scholar 

  • Meerpohl HG, Sauerbrei W, Kühnle H et al. (1991): Cyclophosphamide/ Carboplatin (CTX/CarcoPt) versus cyclophosphamide/cisplatin (CTX/PT) in patients with small volume stage II/IV ovarian cancer (2cm): an interim report by the German Ovarian Cancer Study Group (GOCA). Proc 3 Int Gynecol Cancer Soc 199 (abstract)

    Google Scholar 

  • Meerpohl HG, Lück HJ, Bauknecht Th, du Bois A et al. (1996) Paclitaxel/ carboplatin in der First-line-Behandlung fortgeschrittener Ovarialkarzinome: Ergebnisse einer Dosisfindungsstudie. J Cancer Res Clin Oncol (abstract)

    Google Scholar 

  • Nagell JR van, DePriest PD, Gallion HH, Pavlik EJ (1993) Ovarian cancer screening. Cancer 73: 1523–1528

    Article  Google Scholar 

  • Narod S, Lynch HT, Conway T, Feunteun J, Watson P et al. (1991) Familial breast: ovarian cancer locus on chromosome 17q 12-q23. Lancet 338: 82–83

    Article  PubMed  CAS  Google Scholar 

  • Neijt JP, Burg MEL van der, Vriesendorp R et al. (1984) Randomized trial comparing two combination chemotherapy regimes (hexa-CAF vs CHAP.5) in advanced ovarian carcinoma. Lancet 2: 594–598

    Article  PubMed  CAS  Google Scholar 

  • Neijt JP, ten Bokkel Huinink WW, Burg MEL van der et al. (1987) Randomized trial comparing two combination chemotherapy regimes (CHAP-5 vs CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157

    PubMed  CAS  Google Scholar 

  • Omura G, Blessing JA, Ehrlich CE et al. (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 57: 1725–1730

    Article  PubMed  CAS  Google Scholar 

  • Omura G, Bundy B, Berek J et al. (1989) Randomzed trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 7: 457

    PubMed  CAS  Google Scholar 

  • Omura GA, Buyse M, Marsoni S et al. (1991) CP versus CAP chemotherapy of ovarian carcinoma: a metaanalysis. J Clin Oncol 9: 1668–1991

    Google Scholar 

  • Ovarian Cancer Meta-Analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9: 1668–1674

    Google Scholar 

  • Peters HD, Blatter J, Ermisch S (1995) Gemcitabin: Pharmakologisches Profil und klinische Anwendung. Onkologe 1: 367–382

    Google Scholar 

  • Petterson F (1991) Annual Report of the results of treatment in gynecologic cancer. International Federation of Gynecology and Obstetrics (FIGO), vol 21. Panoramic Press Stockholm

    Google Scholar 

  • Piver ST, Baker TR, Piedmonte M, Sandecki AM (1991) Epidemiology and etiology of ovarian cancer. Semin Oncol 18: 177–185

    PubMed  CAS  Google Scholar 

  • Pujade-Lauraine E, Guastella JP, Colombo N et al. (1991) Intraperitoneal human r-IFN gamma as treatment of ressidual carcinoma after second look ( SLL ). Proc ASCO 10: 195

    Google Scholar 

  • Schwartz PE, Chambers JP, Kohorn EJ et al. (1989) Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. Cancer 63: 1074

    Article  PubMed  CAS  Google Scholar 

  • Sell A, Bertelsen K, Andersen JE et al. (1979) Randomized study of whole abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 37: 67–73

    Google Scholar 

  • Sorbe B, Frankendal B, Veress B (1982) Importance of histologic grading in the prognosis of epithelial ovarian cancer. Obstet Gynecol 59: 576–582

    PubMed  CAS  Google Scholar 

  • Sutton GP, Blessing JA, Photopoulus G, Berman ML, Homesley HD (1990) Gynecologic Oncology Group experience with ifosfomaide. Semin Oncol 17 [Suppl 4]: 6–10

    PubMed  CAS  Google Scholar 

  • Swenerton K, Jeffrey J, Stuart G, Roy M et al. (1992) Cisplatin cyclosphamide versus carboplatin cyclophosphamide in advanced ovarian cancer: a randomized study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 10: 718–726

    PubMed  CAS  Google Scholar 

  • Thigpen T, Vance R, Puneky L, Khansur T (1994) Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55:S 97-S 107

    Article  Google Scholar 

  • Thomas G, Dembo A (1990) Radiation therapy in ovarian cancer. Cancer 71 (4): 1710–1718

    Google Scholar 

  • Tobacman JK, Greene MH, Tucker MA et al. (1982) Intraabdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. Lancet 2: 794

    Google Scholar 

  • Vergote IB, Vergote-deVos LN, Abeler V, Aas M et al. (1992) Randomized trial comparing cisplatin with radioactive phophorus or whole -abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69: 741–749

    Article  PubMed  CAS  Google Scholar 

  • Vermorken JB, Kobierska A, Chevallier B, Zanaboni F et al. (1995) Phase II study of high dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin. Proc ASCO 14: 276 (’ abstract 772)

    Google Scholar 

  • Whitemore AS, Wu ML, Pfaffenberger RS et al. (1988) Personal and environmental characteristics related to epithelial ovarian cancer. Exposures to talcum powder, tabacco, alcohol and coffee. Am J Epidemiol 128: 1228

    Google Scholar 

  • World Health Organization (1989) The world Health Organization collabortive study of neoplasia and steroid contraceptives: epithelial ovarian cancer and combined oral contraceptives. Int J Epidelmiol 18: 538–545

    Article  Google Scholar 

  • Yancik R, Ries LG, Yates JW (1986) Ovarian cancer in the elderly: an analysis of surveillance, epidemiology and end results program data. Am J Obstet Gynecol 154: 639

    PubMed  CAS  Google Scholar 

  • Young RC, Chabner BA, Hubbard SP et al. (1978) Prospective trial of melphalan (L-PAM) versus combination chemotherapy ( Hexa-CAF) in ovarian adenovarcinoma. N Engl J Med 299: 1261–1266

    Article  PubMed  CAS  Google Scholar 

  • Young RC, Decker DG, Wharton JT et al. (1983) Staging laparotomy in early ovarian cancer. JAMA 250: 3072

    Article  PubMed  CAS  Google Scholar 

  • Young R, Walton LA, Ellenburg SS et al. (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 322: 1021

    Article  PubMed  CAS  Google Scholar 

  • Bjorkholm E, Silverswaard C (1981) Prognostik factors in granulosazell tumors. Gynecol Oncol 11:261ff.

    Article  PubMed  CAS  Google Scholar 

  • Colombo N, Sessa C, Landon F et al. (1986) Cisplatin, vinblastine and bleomycine combination chemotherapy in metastatic granulosa cell tumors of the ovary. Obstet Gynecol 67:265ff.

    Article  PubMed  CAS  Google Scholar 

  • Evans AT, Gaffey TA, Malkasian GD et al. (1980) Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 55: 231 ff.

    PubMed  Google Scholar 

  • Fox H, Agrawal K, Langley FA (1975) A clinicopathologic study of 92 cases of granulosazell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 35: 231 ff.

    Article  PubMed  CAS  Google Scholar 

  • Kaye SB, Savies E (1984) Cyclophosphamide, adriamycin and cisplatinum for the treatment of advanced granulosa cell tumor using serum estradiol as tumor marker. Gynecol Oncol 24:261 ff.

    Article  Google Scholar 

  • Klemi PJ, Joensuu H, Salmi T (1990) Prognostic value of flow cytometric DNA content analysis in granulosa cell tumor of the ovary. Cancer 65:1189ff.

    Article  PubMed  CAS  Google Scholar 

  • Lapbohn RE, Burger HG, Bouma J et al. (1989) Inhibin as a marker for granulose cell tumors. N Engl J Med 321:790ff.

    Article  Google Scholar 

  • Slayton RE et al. (1985) Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: A Gynecologic Oncology Group study. Cancer 56: 243ff.

    Article  PubMed  CAS  Google Scholar 

  • Young RE, Scully RE (1980) Ovarian sex cord stromal tumors: recent progress. Int J Gynecol Pathol 1:153 ff.

    Google Scholar 

Download references

Authors
  1. H. G. Meerpohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik, Innere Medizin IV, Abteilung Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, D-06120, Halle/Saale, Deutschland

    Hans-Joachim Schmoll (Direktor) (Direktor)

  2. Klinik und Poliklinik für Innere Medizin II, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, D-07740, Jena, Deutschland

    Klaus Höffken (Direktor) (Direktor)

  3. Medizinischen Klinik II, Schwerpunkt Onkologie und Hämatologie, Humboldt-Universität, Universitätsklinikum Charité, Schumannstraße 20/21, D-10117, Berlin, Deutschland

    Kurt Possinger (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Meerpohl, H.G., du Bois, A. (1997). Epitheliale Ovarialkarzinome. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-12175-7_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-12175-7_48

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-60830-1

  • Online ISBN: 978-3-662-12175-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation